Chinese herbal medicine for miscarriage affects decidual micro-environment and fetal growth

L. Piao a, C.-P. Chen b, C.-C. Yeh c, M. Basar d, R. Masch e, Y.-C. Cheng f, C.J. Lockwood g, F. Schatz g, S.J. Huang a, *

a Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH 43210, USA
b Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan, ROC
c Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
d Department of Obstetrics and Gynecology, Beth Israel Medical Center, New York, NY 10003, USA
e Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA
f Department of Obstetrics and Gynecology, Beth Israel Medical Center, New York, NY 10003, USA
g College of Medicine, South Florida University, Tampa, FL 33620, USA

Article info

Article history:
Accepted 11 February 2015

Keywords:
Chinese herbal medicine
Decidual cells
IUGR
Macrophage
Spontaneous abortion

Abstract

Introduction: Intrauterine growth restriction complicates 5–10% of pregnancies. This study aims to test the hypothesis that Chinese herbal formula, JLFC01, affects pregnancy and fetal development by modulating the pro-inflammatory decidual micro-environment.

Methods: Human decidua from gestational age-matched elective terminations or incomplete/missed abortion was immunostained using anti-CD68 + anti-CD86 or anti-CD163 antibodies. qRT-PCR and Luminex assay measured the effects of JLFC01 on IL-1β- or TNF-α-induced cytokine expression in first trimester decidual cells and on an established spontaneous abortion/intrauterine growth restriction (SA/IUGR)-prone mouse placentae. The effect of JLFC01 on human endometrial endothelial cell angiogenesis was evaluated by average area, length and numbers of branching points of tube formation. Food intake, litter size, fetal weight, placental weight and resorption rate were recorded in SA/IUGR-prone mouse treated with JLFC01. qRT-PCR, Western blot and immunohistochemistry assessed the expression of mouse placental IGF-I and IGF-IR.

Results: In spontaneous abortion, numbers of decidual macrophages expressing CD86 and CD163 are increased and decreased, respectively. JLFC01 reduces IL-1β- or TNF-α-induced GM-CSF, M-CSF, C–C motif ligand 2 (CCL2), interferon-γ-inducible protein-10 (IP-10), CCL5 and IL-8 production in first trimester decidual cells. JLFC01 suppresses the activity of IL-1β- or TNF-α-treated first trimester decidual cells in enhancing macrophage-inhibited angiogenesis. In SA/IUGR-prone mice, JLFC01 increases maternal food intake, litter size, fetal and placental weight, and reduces fetal resorption rate. JLFC01 induces IGF-I and IGF-IR expression and inhibits M-CSF, CCL2, CCL5, CCL11, CCL3 and G-CSF expression in the placentae.

Discussion: JLFC01 improves gestation by inhibiting decidual inflammation, enhancing angiogenesis and promoting fetal growth.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Spontaneous abortion (SA) complicates 15% of human pregnancies. Although chromosomal anomalies account for more than 50% of SA, abnormal fetal development, maternal systemic disorders and environmental insults contribute to its incidence [1]. The mechanisms causing SA remain unknown thereby precluding the development of effective prevention and treatment. Various attempts including immunological approaches [2–6] have not
significantly improved the SA-associated live birth rate. Chinese herbal medicine (CHM) has been widely used in Asia for centuries. Although studies suggest that CMH prevents SA [7], evidence is insufficient to assess the effectiveness of CMH in treating SA. First appearing in Chung-Ching Chang’s “Synopsis of Golden Chamber” about 1800 years ago, JLFC01 is derived from a traditional Chinese formula that successfully treats blood stagnation.

Intrauterine growth restriction (IUGR) complications 5—10% of pregnancies [8]. Many studies indicate that preeclampsia and IUGR [9] are initiated in the first trimester as a consequence of insufficient uteroplacental blood flow to the developing fetal-placental unit and suggest a similar origin for SA. Blastocyst-derived semi-allogeneic extravillous trophoblasts (EVTs) traverse the decidua and inner third of the myometrium and interact with resident decidual cells, decidual natural killer (NK) cells and macrophages. Invading EVTls transform uterine spiral arteries into high-capacitance vessels accompanied by expression of angiogenic factors and microvascular angiogenesis [10]. The resulting increased uterine blood flow to the interstitial space is pivotal for fetal-placental development [9,11]. Disturbances of this environment disrupt early fetal development and elicit long-term complications in affected children.

An abnormal pro-inflammatory decidual micro-environment elicits preeclampsia, SA and IUGR. In addition to mediating spiral artery transformation, decidual macrophages are critical modulators of the immune balance at the fetal–maternal interface. The function, differentiated state and responsiveness of macrophages are governed by their micro-environment and proximity to adjacent cells [12,13]. Generally, macrophage polarization is divided into classically (M1) and alternatively (M2) activated groups [14]. Besides bridging both innate and adaptive immunity, which defend against pathogens, decidual macrophages are important mediators of implantation, placental development and cervical ripening [15]. In early pregnancy, M2 macrophages play a key role in inducing immunotolerance of the fetal semi-allograft [15]. Tight regulation of macrophage trafficking/function plays crucial roles during placentation. Under physiological steady state, macrophages isolated from first trimester decidua are polarized toward an immunotolerant M2 phenotype [16]. By contrast, pro-inflammatory M1 polarization of macrophages is linked to adverse pregnancy outcomes [17]. Our studies indicate that potent pro-inflammatory cytokines, IL-1β and TNF-α, stimulate human first trimester decidual cells (FTDCs) to secrete several chemokines that recruit NK cells [18] and monocytes [19–21]. The decidual cells then promote macrophage differentiation toward an M1 subtype via the regulation of colony-stimulating factors [13].

The current study postulates that these decidual M1 macrophages are integral to the onset of SA and proposes to treat and/or prevent SA by counteracting the resulting pro-inflammatory decidual milieu. Initial observations determined that unlike the dominant M2 immunotolerant macrophage population of normal first trimester human decidua, the decidual macrophage population accompanying SAs displays a pro-inflammatory M1 phenotype. Complementing these in situ observations, the modulating effects of JLFC01 on: 1) IL-1β- or TNF-α-induced expression of several cytokines by FTDCs; 2) FTDCs in modulating human endometrial endothelial cell (HEEC) angiogenesis-inhibiting activity of macrophages were examined. These in vitro observations were extended to include CBA/J x DBA/2 mice, an established SA/IUGR-prone model, in which the effects of JLFC01 ingestion were assessed. An aberrant decidual pro-inflammatory micro-environment [22] can also interfere with normal fetal growth by disrupting fetal programming. The insulin-like growth factors (IGFs) and their receptors are potent regulators of protein turnover, mitogenesis and differentiation [23] and implicated in fetal-placental development [24].

Abnormal IGF expression, malfunctioning IGF receptors or defective downstream signaling pathways are proposed to contribute to the development of IUGR [25]. Thus, the effects of JLFC01 ingestion were compared on placental expression of mRNA and protein levels of IGFs and their receptors in SA/IUGR-prone mice. 2. Methods 2.1. Immunofluorescent staining of decidua for macrophage markers

Decidua was obtained under Institutional Review Board (IRB) approval at Mackay Memorial Hospital, Taipei, Taiwan. Gestational age (GA)-matched tissue was obtained from elective terminations of normal pregnancies between 6 and 12 weeks of gestation without uterine contraction, vaginal bleeding or evidence of fetal demise. Upon diagnosis of missed/incomplete abortion, decidual basalas was evacuated within 24 h from patients without infection or systemic diseases. Serial sections of OCT-embedded specimens were immunostained with mouse anti-human CD68 (1:25, Dako, Carpinteria, CA) followed by Rhodamine–conjugated donkey anti-mouse antibody (1:50, EMD Millipore, Billerica, MA). Sections were then incubated with rabbit anti-human CD163 (1:250, Sigma–Aldrich, St. Louis, MO) or CD86 (1:200, GeneTex, Irvine, CA) followed by corresponding FITC–conjugated secondary antibody (1:100) and 4′,6-diamidino-2-phenylindole (1:500,000, Sigma–Aldrich). Morphometric analysis of cell numbers used Axiovision 3.1 software (Carl Zeiss, Oberkothen, Germany). Five randomly selected fields from each section (three sections/tissue) were examined. Cell numbers per field (3 x 10⁶ pixels²) were counted and calculated as the mean of 15 fields for each tissue. A total of 15 cases per group were examined.

2.2. Cell isolation and culture

FTDCs were isolated and cultured as previously described [20]. Briefly, decidua from elective termination of 6–12 weeks gestation was obtained under IRB approval at The Ohio State University (OSU) and Beth Israel Medical Center, New York, NY. Cells were purified using Ficoll-Hipaque Plus (GE Healthcare, Piscataway, NJ). CD45 staining confirmed the absence of leukocytes. Cultured FTDCs were found to be vimentin-positive and cytokeratin-negative and displayed morphological changes and enhanced prolactin and plasminogen activator inhibitor-1 as well as inhibited interstitial collagenase and stromelysin-1 expression with prolonged tissue factor expression during incubation with a progestin. Confluent FTDCs were primed with estradiol (10⁻⁸ M) and medroxyprogesterone acetate (10⁻² M) for 7d and pre-treated with or without 1.25 μg/ml of a Chinese herbal formula, JLFC01, for 24 h then incubated with 1 ng/ml of IL-1β or TNF-α (R&D Systems, Minneapolis, MN) with or without JLFC01. JLFC01 was manufactured from herbs and processed in stainless steel extractors at a low temperature (below 100 °C) in order to preserve the activity of essential ingredients and create a water decoction. This procedure follows the sequence described in canonical Chinese medicine book since the sequence of the herbs process within a decoction determines the efficacy of the formula. The extracted liquid is then spray dried to form a powder. This procedure follows good manufacturing practice (GMP) guidelines. In addition, both the presence and levels of heavy metal and microbes are also assessed. Conditioned medium (CM) supernatants were collected. Monocytes were isolated from peripheral blood of healthy reproductive age female donors using Ficoll-Hipaque and purified using anti-CD14-paramagnetic beads according to the manufacturer’s instructions (Miltenyi Biotech, Auburn, CA).

For HEECs [26], blood vessels in the endometrium obtained from hysterectomy for myomas was dissected, then, minced and digested with type VII collagenase/ dispase/DNase I followed by filtration through a 70-μm cell strainer. The cells were labeled with biotinylated UEA-1 (Ulex europaeus) lectin, and then, separated from non-labeled cells by panning on activated surface/AIS MicroCellector flasks coated with streptavidin. Cells were cultured in EBM-2 medium supplemented with 15% fetal calf serum.

2.3. Cell proliferation assay

Cell proliferation was examined using a CellTiter 96 One Solution Cell Proliferation Assay (Promega, Madison, WI). Briefly, FTDCs were treated with vehicle, 0.08, 0.16, 0.31, 0.63, 1.25, 2.5, 5 or 10 ng/ml of JLFC01 for 48 h. Absorbance was detected at 490 nm after adding MTS reagent.

2.4. Bio-Plex assay

Bio-Plex assays (Bio-Rad, Hercules, CA) measured CM-CSF, M-CSF, C–C motif ligand 2 (CCL2), interferon-γ-inducible protein-10 (IP-10), CCL5 and IL-8 levels in CM from different cultures as well as M-CSF, CCL11, CCL2, CCL5, C-C and C–CSF levels in mouse placenta lysates. Data acquisition and analyses were completed with the Bio-Plex 200 system using Bio-Plex Manager Software v6. Bicinchoninic acid protein assay (Thermo scientific, Rockford, IL) measured total cell protein levels.

2.5. Quantitative RT-PCR (qRT-PCR)

Total RNA was extracted using total RNA purification plus kit (Norgen Biotek, ON, Canada). Reverse transcription used SuperScript™III First-Strand Synthesis...
System from Invitrogen. Specific primer sets for human GM-CSF, M-CSF, CCL2, IP-10, CCL5, IL-8 or β-actin and mouse M-CSF, CCL11, CCL2, CCL3, CCL5, G-CSF or β-actin (Integrated DNA Technologies, Coralville, IA) (Supplementary Table 1) were used for qPCR using SYBR® green-based detection. Quantitation of unknowns was determined and adjusted to quantitative expression of β-actin in the specific samples. Melting curve analysis determined the specificity of the amplified products and the absence of primer-dimer formation.

2.6. Angiogenesis assays

CM from FTDCs was treated with anti-IL-1β or anti-TNF-α neutralizing antibody (R & D Systems) followed by protein G-sepharose (Sigma–Aldrich, St. Louis, MO) treatment. Macrophages were first cultured with CM from FTDCs ± JLFC01 ± IL-1β or TNF-α for 2d and then co-cultured with HEECs for 8 h. To test whether JLFC01 had a direct effect on angiogenesis, macrophages were incubated with CM from FTDCs without JLFC01 treatment for 2d followed by co-culture with HEECs pretreated ± 1.25 μg/ml JLFC01 for 8 h. The culture wells were coated with growth factor-reduced Matrigel (BD Biosciences, San Jose, CA). Tube formation was assessed by measuring average area, length and number of branching points using AngioTool software (NCI) [27].

2.7. Mouse studies

Studies were performed under OSU Institutional Animal Care and Use Committee approval. Eight-week-old virgin female CBA/J mice were treated with 0.3 gm/kg body weight/d of JLFC01 dissolved in ddH₂O, compared to 1 25 g/ml JLFC01 for 8 h. The culture wells were coated with growth factor-reduced Matrigel (BD Biosciences, San Jose, CA). Tube formation was assessed by measuring average area, length and number of branching points using AngioTool software (NCI) [27].

2.8. Immunohistochemistry of mouse placental IGF-I & IGF-IR

Deparaffinized formalin-fixed sections were incubated with goat serum (Lab-Vision, Fremont, California), then, rabbit anti-IGF-I (1:2,400, Aviva System Biology, San Diego, CA), Anti-IGF-IR antibody or IgG isotype (1:2,400, Cell Signaling Technology, Beverly, MA). Biotinylated goat anti-rabbit antibody (1:400, Vector Laboratories, Burlingame, CA) was added. The antigen–antibody complex was detected using a streptavidin–avidin–biotin–peroxidase kit and 3,3-Diaminobenzidine tetrahydrochloride dihydroxide (Vector Laboratories) with hematoxylin counterstaining.

2.9. Statistics

The variance and normality of data from immunohistochemical staining, qRT-PCR, Luminex assay, angiogenesis assay, mouse studies, densitometry and H-scores of anti-proliferation effects in subsequent in vitro experiments, FTDCs were pre-incubated with 1.25 μg/ml of JLFC01 for 24 h and then treated with IL-1β or TNF-α for an additional 24 h.

![Fig. 1](image)

**Fig. 1.** Macrophages polarized toward M1 subtype in the decidua from patients with SA. Representative photomicrographs of immunofluorescent staining of M1 macrophage markers, (A, B), CDB8 (green) and M2 macrophage marker, (C, D) CD163 (green), were performed under OSU Institutional Animal Care and Use Committee approval. Eight-week-old virgin female CBA/J mice were treated with 0.3 gm/kg body weight/d of JLFC01 dissolved in ddH₂O, compared to 1 25 g/ml JLFC01 for 8 h. The culture wells were coated with growth factor-reduced Matrigel (BD Biosciences, San Jose, CA). Tube formation was assessed by measuring average area, length and number of branching points using AngioTool software (NCI) [27].

**Fig. 2** shows profound enhancement by either IL-1β or TNF-α of mRNA expression of several pro-inflammatory cytokines was blunted during co-incubation with JLFC01 (n = 3–11, Supplementary Table 2). Specifically, IL-1β and TNF-α induced GM-CSF expression by 4.5- and 10.19-fold, respectively. This induction was correspondingly reduced by 51% and 81% by JLFC01 treatment (Fig. 2A). M-CSF expression enhanced by IL-1β (6.34-fold) or TNF-α (4.21-fold) was suppressed by 55% and 56%, respectively, by JLFC01 (Fig. 2B). Fig. 2C demonstrates that IL-1β elicited a 24.99-fold and TNF-α up-regulated a 15.74-fold increase of CCL2 expression. JLFC01 treatment decreased this activation by 49% (by IL-1β) and 45% (by TNF-α) though inhibition of TNF-α-induced CCL2 expression only attained borderline statistical significance. For IP-10 expression, Fig. 2D indicates a 6.39- and 10.04-fold increase by IL-1β and TNF-α, respectively. JLFC01 correspondingly inhibited IL-1β- and TNF-α-stimulated IP-10 expression by 53% and 79%. The expression of CCL5 and IL-8 was promoted in response to IL-1β by 3.58- and 5483.77-fold, respectively, whereas JLFC01 suppression of this induction only attained borderline statistical significance. For IP-10 expression, JLFC01 significantly repressed TNF-α-induced CCL5 (8.37-fold) and IL-8 (326.60-fold) expression by 91% and 63%, respectively (Fig. 2E, F).

In parallel incubations, protein expression levels of GM-CSF, M-CSF, CCL2, IP-10, CCL5 and IL-8 were measured by Bio-Plex assays (Fig. 2G–L, n = 3–11, Supplementary Table 2). In FTDCs, IL-1β, and IL-8 induced GM-CSF, M-CSF, CCL2, IP-10, CCL5 and IL-8 production by 7.5-, 8.78-, 52.9-, 73.49-, 545.9- and 186.2-fold, respectively. JLFC01 suppressed this induction by 62%, 56%, 17%, 98%, 91% and 38%, respectively. Similarly, GM-CSF, M-CSF, CCL2, IP-10, CCL5 and IL-8 production was up-regulated by TNF-α by 3.196, 8.5, 6.7, 7.7, 14.9 and 14.3-fold, respectively.
3.3. JLFC01 suppresses the activity of IL-1β- or TNF-α-treated FTDCs in enhancing angiogenesis-inhibiting activity of macrophages

To test potential interactions among different cell types, macrophage-regulated angiogenesis was determined by first incubating macrophages with CM from IL-1β- or TNF-α-stimulated FTDCs ± JLFC01 followed by co-culturing with HEECs in an angiogenesis assay. Direct effects of JLFC01 on HEECs were also assessed by co-culturing macrophages treated with CM from IL-1β- or TNF-α-stimulated FTDCs and JLFC01-treated HEECs in an angiogenesis assay (n = 4). Fig. 3A indicates average tube area was increased by macrophages incubated with CM derived from FTDCs treated with IL-1β or TNF-α, while JLFC01 blocked the effects. Consistently, other angiogenesis measurements, i.e. tube length (Fig. 3B) and number of branching points (Fig. 3C), were reduced by macrophages incubated with CM from FTDCs treated with IL-1β or TNF-α. Co-incubation of FTDCs with JLFC01 reversed this effect. However, JLFC01 treatment of HEECs did not affect any of the three parameters (Fig. 3A, B, C) in HEECs co-cultured with macrophages pre-incubated with CM from IL-1β- or TNF-α-stimulated FTDCs.

3.4. JLFC01 prevents placental pro-inflammatory cytokine production, miscarriage and improves fetal-placental growth as well as maternal food intake in SA/IUGR-prone mice

JLFC01 ingestion: i) inhibits placental expression of M-CSF (Fig. 4A and G), CCL11 (Fig. 4B and H), CCL2 (Fig. 4C and I), CCL3 (Fig. 4D and J), CCL5 (Fig. 4E and K) and G-CSF (Fig. 4F and L) (mRNA: 1.96 x, 5.96x, 618.39x, 1.93x, 3.37x and 5.36x, respectively, n = 5 - 8; protein: 1.40x, 2.07x, 74.69x, 2.11x, 1.29x and 1.50x, respectively, n = 18 - 20); ii) increased litter size (Fig. 5A), fetal (Fig. 5B) and placental weight (Fig. 5C) by 35.56%, 50.92% (from 1.86 to 2.80 gm) and 28.20% (from 356.5 to 438.7 mg), respectively, accompanied by a 40.44% fetal resorption rate reduction (Fig. 5D); iii) increased food intake by 19.6%, 10.8% and 27.8% at GD5, GD10 and GD15, respectively (Fig. 5E) (n = 3). Potential mechanisms responsible for increased fetal growth accompanying JLFC01 ingestion were examined by placental IGF-I and IGF-IR expression. Steady state mRNA levels of IGF-I and IGF-IR are up-regulated by JLFC01 treatment by 2.2- and 2.1-fold, respectively (Fig. 6A and B), with Western blot revealing parallel effects on IGF-I and IGF-IR protein expression (Fig. 6C and D) (n = 3). Immunohistochemistry demonstrates that IGF-I (Fig. 6F and I) and IGF-IR (Fig. 6H and J) expression in the placentae are consistently enhanced by JLFC01 ingestion (n = 3).

4. Discussion

Successful pregnancy and adequate fetal growth require maintenance of homeostasis and immune balance at the maternal–fetal interface. Conditions disrupting this equilibrium are implicated in eliciting shallow placentation accompanied by SA, IUGR and preeclampsia. These human pregnancy complications are associated with induction of depression, stress, anxiety and lower self-esteem in affected couples, while imposing a financial burden on affected families and society [28]. The pathogenesis of SA and IUGR are multi-factorial with the underlying mechanisms poorly understood. Immunological [2], nutritional [29], hormonal [30], and
surgical [31] interventions are ineffective in either preventing or treating SA and IUGR.

JLFC01 used in this study was modified from a traditional formula, Guizhi Fuling Wan, containing the same herbs described in canonical Chinese medicine books. However, the dosages and extracting procedures vary among different pharmaceutical companies and can potentially affect the efficacy. Therefore, JLFC01 was chosen as the name of this preparation manufactured by Brion Research Institute to avoid confusion. Despite centuries long use in Asia of JLFC01 to effectively treat SA with minimal side effects, the mechanisms and components in the herbs responsible for its actions are understudied and consequently not understood. To elucidate this question, the current study integrates in vitro observations on primary human cells with in vivo observations on an SA/IUGR-prone mouse model. The latter demonstrates that JLFC01 induces novel effects by improving growth of the fetal-placental unit and increasing maternal food intake, thus complementing its historical effectiveness in preventing SA. Initial assessment by immunofluorescent staining revealed that, consistent with a local pro-inflammatory milieu, first trimester decidual macrophages are

Fig. 3. JLFC01 suppresses the activity of IL-1β- (EMI) or TNF-α- (EMT) treated FTDCs in enhancing angiogenesis-inhibiting activity of macrophages. HEECs treated with or without JLFC01 co-cultured with macrophages incubated with CM from IL-1β- or TNF-α-treated FTDCs in the presence or absence of JLFC01 were grown on Matrigel for 8 h. Angiogenesis was assessed by measuring (A) average area (µm²), (B) length (µm) and (C) numbers of branching points (5 random fields/well). The results are reported as mean ± SEM. n = 4; *: vs. EM, #: vs. EMI or EMT. ##p < 0.01, ###p < 0.005.

Fig. 4. JLFC01 inhibits M-CSF, CCL11, CCL2, CCL3, CCL5 and G-CSF expression in placentae from mice with SA/IUGR. (A–F) The mRNA expression was measured by qRT-PCR. (G–L) The protein levels of each individual cytokines in placentae from mice with SA/IUGR were measured by multiplex Bio-Plex assay and normalized to total cell protein. The results are reported as mean ± SEM. n = 5–8 for qRT-PCR; n = 18–20 for Bio-Plex assay. *p < 0.05, **p < 0.01, ***p < 0.005.
Fig. 5. JLFC01 reduces spontaneous abortion and improves fetal growth. (A) litter size, (B) fetal weight, (C) placental weight, (D) fetal resorption and (E) maternal food intake at gestational day (GD) 5, 10 and 15 of CBA/J mice treated with JLFC01. The results are reported as mean ± SEM. n = 3; *p < 0.05, ***p < 0.005.

Fig. 6. JLFC01 increases IGF-I and IGF-1R expression in the placenta of CBA/J mice. Placental IGF-I and IGF-IR expression was evaluated by (A, B) qRT-PCR, (C, D) Western blot with densitometry. The expression of IGF-I and IGF-IR in placenta from CBA/J mice treated in the absence (E, G) or presence (F, H) of JLFC01 was evaluated by immunohistochemistry (400×). IGF-I and IGF-IR immunoreactivity was semi-quantitatively evaluated using the following intensity categories: 0, no staining; +, weak but detectable staining; ++, moderate or distinct staining; and ++++, intense staining. (I, J) A histological score (HSCORE) was calculated using the formula HSCORE = Σ(Pi x i), where i represents the intensity scores, and Pi is the corresponding percentage of the cells. Five fields/slide were evaluated by 2 investigators blinded to the tissue source. The results of densitometry and immunohistochemistry are reported as mean ± SEM. n = 3; *p < 0.05; ***p < 0.005. Inset: IgG control; Scale bar: 50 μm.
polarized toward an M1 subtype in SA. Previously, our laboratory found that stimulation of FTDCs with TNF-α or IL-1β enhances macrophage-induced EVT apoptosis as well as decidual macrophage and dendritic cell recruitment/activation [13,20,21]. These observations implicate TNF-α and IL-1β-stimulated decidual cells in the pathogenesis of pregnancy complications [13]. In the current study, incubation of FTDCs with JLFC01 inhibited both TNF-α and IL-1β-induced production of cytokines associated with monocyte and NK cell recruitment and activation, suggesting that JLFC01 improves pregnancy outcomes and fetal growth by exerting broad anti-inflammatory activities. Consistently, JLFC01 treatment suppressed mouse placental production of pro-inflammatory cytokines, suggesting an association with its roles in improving pregnancy and fetal growth.

EVT invasion of the decidua and underlying myometrium acting in concert with robust angiogenesis are critical to successful placentation. In addition to leukocyte recruitment and activation, specific cytokines up-regulated by IL-1β or TNF-α in FTDCs were shown to exert mixed angiogenic effects. Specifically, GM-CSF, M-CSF and IL-8 promote [32], whereas IP-10 suppresses [33], angiogenesis and endothelial cell proliferation. Moreover, IL-8 inhibits [34], while CCL2 and IP-10 [33,35] increase, endothelial cell apoptosis. The net effect of JLFC01 on secreted angiogenesis-regulating cytokines by FTDCs under the modulating influence of IL-1β or TNF-α has yet to be determined. Moreover, in early pregnancy, decidual macrophages and FTDCs are positioned to affect angiogenesis [36,37]. The current use of primary HEECs to test angiogenesis found that CM derived from IL-1β- or TNF-α-treated FTDCs enhances the angiogenesis-inhibiting activity of macrophages. However, treatment of FTDCs with JLFC01 reverses this effect, suggesting that JLFC01 improves placentation by promoting decidual angiogenesis. The current study used blood drawn from non-pregnant healthy reproductive age women. Ideally, blood, first trimester decidual cells and HEECs should all be obtained from the same woman receiving elective termination. However, both ethical proscriptions and varying locations of sample collection present a major practical obstacle in obtaining blood as well as sufficient tissue for the isolation of decidual cells and HEECs from the same patient. Thus, in recruiting the donors for blood and tissue, cells were isolated from individuals with similar physiological characteristics using the same inclusion/exclusion criteria.

In addition to implantation, JLFC01 may aid pregnancy by directly targeting the embryo and/or by modifying fetal programming to improve fetal growth. Critical windows of developmental plasticity are initiated pre-conceptually and extend through early postnatal life [38]. Fetal programming encompasses the role of developmental plasticity in response to environmental and nutritional signals during early life and its potential adverse consequences in later life [38]. The maternal contribution to the nutritional, hormonal and metabolic fetal environment is crucial to fetal growth [39]. Disturbances in related mechanisms can impede early fetal development with potential long-term outcomes and pregnancy complications [39]. Increasing evidence indicates an association of such fetal growth pathologies as IUGR and small-for-gestational-age fetuses with changes in placental transporter function [39]. Previous attention has generally focused on the molecular mechanisms underlying programming effects with the goal of development of targeted therapy in the population at risk [40].

Decreased maternal serum IGF-I levels are suggested to be associated with poor placental function, but not low birth weight [41]. Both IGF-I and IGF-II play crucial roles in fetal-placental growth throughout pregnancy [42]. However, previous studies provide conflicting results. Specifically, IGF-I and IGF-II expression levels are increased in term placentae associated with IUGR [43], whereas immunohistochemistry studies revealed conserved distribution of the IGF-I receptor in placentae from normal pregnancies and pregnancies associated with IUGR [44]. Although inconsistent with results from other studies [43], the increase of placental IGF-I and IGF-1R accompanying increased fetal and placental weight by JLFC01 in the SA/IUGR-prone mice used in the current study indicates an association of IGF-I with fetal growth that is regulated by JLFC01. These conflicting observations suggest a need to test the direct effects of JLFC01 on the embryo. Moreover, the current study found that JLFC01 improves maternal food intake in pregnant mice prone to SA/IUGR, thus, mandating further investigations of the regulation of nutrient transport machinery at the maternal–fetal interface by JLFC01.

In summary, the centuries-long use of JLFC01 to treat such diverse ailments as blood stagnation and threatened abortion attest to its unprecedented safety record. This study confirms its protective effects during gestation and reveals a novel effect on fetal development. The current findings also suggest mechanisms that maintain pregnancy and improve fetal growth. Further studies are required to uncover critical regulatory mechanisms by which JLFC01 prevents SA by focusing on key processes necessary to maintain pregnancy at the implantation site, i.e. angiogenesis, macrophage polarization, and fetal programming and the active components of JLFC01. In addition to FTDCs, HEECs and macrophages, other cell types in the decidua, including various immune cells, vascular smooth muscle cells, EVTs, and glandular cells may also be targets for JLFC01, indicating the need to test the effects of JLFC01 on these cell types.

Conflict of interest
The authors report no conflict of interest.

Acknowledgments
The authors report no conflict of interest. However, the authors were advised by Brion Research Institute not to reveal the herbal components included in the formulation.

We thank the Brion Research Institute for providing JLFC01 and assistance of Dr. Pai-Lien Chen at Family Health International in statistical data analysis. This work was supported by grant 5R01HD056123 from NICHD, NIH (S.J.H.). The authors also gratefully acknowledge the editorial assistance provided by Mr. John Shapiro at The Ohio State University.

Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.placenta.2015.02.006.

References


